Identification and clinical staging of prostatic neoplasms is performed with a combination of diagnostic tests, including digital rectal examination, serum prostatic specific antigen (PSA), and histological analysis of tumor biopsies with grading according to the Gleason system [2–9]. Here, PROS1 is linked to neoplasm.